Already a DIA Member? Sign in. Not a member? Join.
Sign in
Not a Member?
Translating Clinical Trials into Clinical Benefit
Air Date: Jan 03, 2020Why translating biologics into therapeutics will lead next wave of oncology treatments and other treatments for more common disease.
Speaker(s)
Gary L. Kelloff
Special Advisor
National Cancer Institute
Gary J. Kelloff, MD, has worked for more than 40 years in cancer research at the National Cancer Institute, and is a special advisor for the NCI Division of Cancer Treatment and Diagnosis, working on strategies for developing biomarkers for oncology drug development and cancer patient management. Dr. Kelloff leads several collaborations with FDA and industry on drug development strategies, and, since 2009, has co-chaired ongoing efforts under the Foundation for the National Institutes for Health Biomarkers Consortium to create public-private partnerships to define biomarker use in cancer drug development and patient management. He is also involved in on-going efforts to establish protocol and assay standardization for biomarker evaluation.